Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025. Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Show more...
FAQ
Kancera AB 今天的股價是多少?▼
3EE0.MU 目前價格為 €0.00 EUR,過去 24 小時上漲了 +0%。在圖表上更密切關注 Kancera AB 股價表現。
Kancera AB 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Muenchen 交易所,Kancera AB 的股票以代號 3EE0.MU 進行交易。
Kancera AB 的市值是多少?▼
今天 Kancera AB 的市值為 460,506.8
Kancera AB 去年的營收是多少?▼
Kancera AB 去年的營收為 0EUR。
Kancera AB 去年的淨利是多少?▼
3EE0.MU 去年的淨收益為 -4.3MEUR。
Kancera AB 有多少名員工?▼
截至 August 31, 2026,公司共有 5 名員工。
Kancera AB 位於哪個產業?▼
Kancera AB從事於Other產業。
Kancera AB 何時完成拆股?▼
Kancera AB 最近沒有進行任何拆股。
Kancera AB 的總部在哪裡?▼
Kancera AB 的總部位於 瑞典 的 Solna。